Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia

Molecular Medicine Reports - Greece
doi 10.3892/mmr.2016.5111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Discovering Gene Expression Signatures Responding to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia

BMC Medical Genomics
Genetics
2016English

Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Oncologist
Cancer ResearchMedicineOncology
2019English

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Exerts Immunomodulatory Activity Towards Tumor-Infiltrating Macrophages

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

the Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies

Haematologica
Hematology
2017English

Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy